VANCOUVER, British Columbia, Feb. 10, 2020 /PRNewswire/ — Bold Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that it has received clearance from Health Canada to initiate a Phase 1b trial of… Read More
Arbutus expects to announce AB-729 Preliminary Phase 1a/1b Data late Q12020 WARMINSTER, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), announced today its decision to discontinue AB-452, its first generation… Read More
SEATTLE, Feb. 06, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate… Read More
Vancouver, British Columbia, February 4, 2020 – The Vancouver Prostate Centre is launching a collaboration with Roche and PHEMI Systems aimed at finding new insights into precision medicine and oncology treatment with help from the most advanced technology in… Read More
SAN DIEGO, Feb. 5, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that… Read More
